Dyspareunia

05/24/2001 - "These metabolically labile estrogens will be extremely useful for the therapeutic treatment of the vaginal dyspareunia of menopause in women for whom systemic estrogens are contraindicated."
10/01/2001 - "Conjugated estrogen cream showed superior efficacy in alleviating vaginal dryness and dyspareunia. "
08/15/2015 - "Estrogen is effective for the treatment of dyspareunia associated with genitourinary syndrome of menopause. "
08/01/2015 - "A comparison between vaginal estrogen and vaginal hyaluronic for the treatment of dyspareunia in women using hormonal contraceptive."
10/01/2013 - "Seventy-one percent (15/21) of postmenopausal women reported vestibular dyspareunia related to a drop in estrogen either with menopause (13/21) or previously, postpartum (2/21). "

01/01/2014 - "Results of Phase III clinical trials showed that ospemifene significantly improved the vaginal maturation index (decreased parabasal cells and increased superficial cells), decreased vaginal pH, and decreased severity of the self-identified most bothersome symptom (dyspareunia or vaginal dryness) compared to placebo. "
06/01/2013 - "Analysis of the intent-to-treat (n = 605) population found the efficacy of ospemifene to be significantly greater than that of placebo for each of the following coprimary endpoints: percentages of parabasal and superficial cells, vaginal pH, and severity of dyspareunia. "
10/01/2014 - "Several studies have evaluated the effects of ospemifene on VVA and dyspareunia and indicate an improvement in subjective findings. "
12/01/2015 - "This is a comprehensive review describing the clinical safety and efficacy of ospemifene for the treatment of dyspareunia and VVA. "
10/01/2014 - "In this review, current evidence for the safety and efficacy of ospemifene in the treatment of moderate-to-severe VVA and dyspareunia are evaluated. "

05/01/2013 - "The effect of conservative surgery at laparoscopy versus treatment with a low dose of norethisterone acetate per os (2.5 mg/day) in women with persistent/recurrent severe deep dyspareunia after first-line surgery was compared. "
12/01/2012 - "The effect of conservative surgery at laparoscopy was compared with treatment with a low-dose of norethisterone acetate per os (2.5 mg/day) in women with persistent/recurrent severe deep dyspareunia after first-line surgery. "
01/01/2010 - "Norethisterone acetate determined a significant improvement in the intensity of chronic pelvic pain, deep dyspareunia, dyschezia. "
01/01/1998 - "The purpose of the study was to evaluate the efficacy of norethindrone acetate (NA) treatment in 52 women with dysmenorrhea, dyspareunia, noncyclic pelvic pain who had a diagnosis of endometriosis by laparoscopy. "
01/01/2011 - "One patient preference study demonstrated that letrozole combined with norethisterone acetate is more effective in reducing pain and deep dyspareunia than norethisterone acetate alone. "

01/01/1984 - "Neither the vasomotor complaints nor dyspareunia correlated with the hormone levels or cytology findings to such an extent as to be helpful in planning treatment. "
11/01/2009 - "Hormone therapy seems to improve vaginal lubrication and dyspareunia. "
07/01/2009 - "Dyspareunia was associated with educational attainment, employment status, menopause status, current hormone therapy use, genitourinary symptoms, and loss of libido (P < 0.05). "
01/01/1984 - "Climacteric symptomatology was investigated in a group of non-selected women aged between 54 and 56 years of age, Vasomotor complaints and dyspareunia, in particular, were noted and related to plasma hormone levels and vaginal cytology. "
05/01/2010 - "After the study was published, the use of systemic hormone therapy dramatically decreased resulting in an increased incidence of menopausal symptoms such as hot flashes, vaginal dryness, and dyspareunia experienced by women. "

06/01/2013 - "Lubricants are usually used during sexual intercourse to provide temporary relief from vaginal dryness and dyspareunia; however, they have no long-term therapeutic effects. "
09/01/2010 - "Vaginal moisturizers and lubricants also provide symptomatic relief for vaginal dryness and dyspareunia, respectively."
01/01/2012 - "The aim of this study was to examine differences between women with and without dyspareunia in self-reported natural lubrication and attitudes toward and use of personal lubricants. "
01/01/2012 - "Lubricants were rated as less effective among women with dyspareunia vs. controls across all reported reasons for use. "
10/01/2008 - "Non-oestrogenic vaginal lubricants seem to moderately decrease occurrence of vaginal dryness and dyspareunia. "

01/01/2015 - "There were significant improvements in libido and dyspareunia with the intravaginal use of DHEA that contribute to improved quality of life for postmenopausal women. "
07/01/2014 - "Lack of influence of dyspareunia on the beneficial effect of intravaginal prasterone (dehydroepiandrosterone, DHEA) on sexual dysfunction in postmenopausal women."
04/01/2011 - "Intravaginal dehydroepiandrosterone (prasterone), a highly efficient treatment of dyspareunia."
01/01/2015 - "While daily intravaginal administration of 0.50% (6.5 mg) dehydroepiandrosterone (DHEA, prasterone) for 12 weeks has shown clinically and statistically significant effects on moderate to severe (MS) dyspareunia as the most bothersome symptom (MBS), the present study analyzes the effect of a reduced dosing regimen on MBS vaginal dryness. "
09/01/2015 - "This study aims to confirm the local effects of intravaginal prasterone on moderate to severe dyspareunia, a symptom of vulvovaginal atrophy (VVA) associated with menopause. "

11/01/2000 - "Round ligament plication is safe and effective in patients with retroverted uteri and dyspareunia or CPP."
08/04/2008 - "Self-reports of dysmenorrhoea, dyspareunia, and any other CPP not associated with sexual intercourse or menstruation. "
11/01/2006 - "At same times, a significant (P<0.01) decrease in severity of CPP and deep dyspareunia was observed in both groups with no difference between them. "
11/01/2006 - "Cure rate, severity of CPP, and deep dyspareunia were also evaluated after 6 and 12 months from surgery. "
01/01/2005 - "CPP is clinically manifested with dysmenorrhoea, dyspareunia and postcoital ache. "

06/01/2015 - "Depending upon the degree of ER agonism/antagonism at the target tissue, SERMs show efficacy for various indications including osteoporosis, dyspareunia, and breast cancer, and are associated with safety risks. "
11/01/2014 - "Today there are 5 SERMs FDA approved (one other in Europe) for applications ranging from the reduction of breast cancer risk and osteoporosis to the reduction of menopausal hot flashes and improvements in dyspareunia and vaginal lubrication. "
04/01/2015 - "Ospemifene, a selective estrogen receptor modulator, approved to treat dyspareunia at menopause, is also discussed. "
09/01/2014 - "Ospemifene is a novel, oral selective estrogen receptor modulator that has been approved in the USA for treatment of dyspareunia. "
09/01/2014 - "Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia."

07/01/2014 - "Isoflavone vaginal gel was effective for relief of vaginal dryness and dyspareunia symptons and an increase in the intermediate and superficial cells was noted. "
03/01/2013 - "Isoflavone vaginal gel appears to be effective for relief of vaginal dryness and dyspareunia symptoms and an increase in the intermediate and superficial cells was noted. "
08/01/2011 - "[Evaluation of an estrogen vaginal cream for the treatment of dyspareunia: a double-blind randomized trial]."
08/01/2011 - "Applying a vaginal cream, whether it contains estrogens or not, for six weeks lessens dyspareunia. "
01/01/1991 - "After the first year all women complaining of dyspareunia were treated with Estriol vaginal cream. "

01/01/2014 - "In this prospective, randomized, controlled clinical trial in minimally invasive surgery research center, 51 women with pelvic endometriosis and endometriotic pain (dyspareunia, dysmenorrhea, pelvic pain) score of 5 or more (for at least one of these endometriotic pain), after laparoscopic diagnosis and conservative laparoscopic surgery were treated with either Letrozole plus OCP (n=25) or only OCP (n=26) for 4 months continuously. "
01/01/2011 - "One patient preference study demonstrated that letrozole combined with norethisterone acetate is more effective in reducing pain and deep dyspareunia than norethisterone acetate alone. "
12/01/2009 - "The combination drug regimen was more effective in reducing pain and deep dyspareunia than norethisterone acetate; however, letrozole caused a higher incidence of adverse effects, cost more and did not improve patients' satisfaction or influence recurrence of pain."

05/01/2015 - "The aim was to study dyspareunia and sexual function at 3-12 months after vaginal delivery in Thai primiparous women with episiotomy. "
10/01/2013 - "The aim of the present study was to assess the impact of an episiotomy on the development of postpartum dyspareunia and anal incontinence. "
05/01/2015 - "Dyspareunia at 3 months is common in Thai primiparous women with episiotomy. "
05/01/2015 - "Dyspareunia and sexual dysfunction after vaginal delivery in Thai primiparous women with episiotomy."
03/01/2015 - "Dyspareunia was more frequent in case of episiotomy, perineal tear during the delivery and delivery assisted (vacuum). "

09/01/2012 - "Dyspareunia and local sensitivity were evaluated before, at the end, and 90 days after treatment. "
11/01/2007 - "Score of dyspareunia in Group A and C was obvioushy lower than that in Group B after treatment (P <0.01). "
05/01/2005 - "Among the 13 women managed nonsurgically who had resolution of the fissure, 7 women were sexually active after treatment and dyspareunia resolved in 2 (29%) women. "
08/01/2004 - "After treatment only 3 of 30 (10%) of the evaluable men had dyspareunia. "
01/01/2003 - "Of the women who had ever had prolonged and severe dyspareunia 28% had consulted a physician for their symptoms; 20% recovered after treatment, while 31% recovered spontaneously. "

07/01/2011 - "Of the women included in the study, 84.5% reported an improvement of dyspareunia after only five applications of TENS, with a total remission of symptoms (in 95% of patients) at the end of the protocol. "
07/01/2011 - "Effect of transcutaneous electrical nerve stimulation on the postpartum dyspareunia treatment."
11/01/2015 - "We observed significant improvement for chronic pelvic pain, deep dyspareunia and quality of life by the use of TENS. "
07/01/2011 - "Therapy with intravaginal transcutaneous nerve stimulation and pelvic floor relaxation exercises is safe and effective in the improvement of vulvar pain and dyspareunia in women with postpartum perineal trauma due to episiorrhaphy, after spontaneous delivery."
11/01/2015 - "Both resources (acupuncture-like TENS and self-applied TENS) demonstrated effectiveness as a complementary treatment of pelvic pain and deep dyspareunia, improving quality of life in women with deep endometriosis regardless of the device used for treatment."

04/01/2001 - "This study compared group cognitive-behavioral therapy (12-week trial), surface electromyographic biofeedback (12-week trial), and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis. "
04/01/2001 - "A randomized comparison of group cognitive--behavioral therapy, surface electromyographic biofeedback, and vestibulectomy in the treatment of dyspareunia resulting from vulvar vestibulitis."
12/01/2008 - "The pelvic floor relaxation with biofeedback and ellectroanalgesia is safe and effective in improvement in vulvar pain and dyspareunia in women with vulvodynia."
09/01/2007 - "Treating provoked vestibulodynia by either topical lidocaine or electromyographic biofeedback increased vestibular pain thresholds, reduced dyspareunia, and improved bodily pain. "

07/01/2004 - "Although cesarean section at full dilatation does not completely protect women from pelvic floor morbidity, those that followed instrumental delivery had a significantly greater prevalence of urinary symptoms and dyspareunia. "
05/01/2015 - "Herein a rare case of dyspareunia and urinary symptoms is described, which started following a lower segment cesarean section (LSCS). "
04/01/2015 - "Compared with women who had a spontaneous vaginal delivery with an intact perineum or unsutured tear, women who had an emergency caesarean section (adjusted odds ratio [aOR] 2.41, 95% confidence interval [95% CI] 1.4-4.0; P = 0.001), vacuum extraction (aOR 2.28, 95% CI 1.3-4.1; P = 0.005) or elective caesarean section (aOR 1.71, 95% CI 0.9-3.2; P = 0.087) had increased odds of reporting dyspareunia at 18 months postpartum, adjusting for maternal age and other potential confounders. "
12/01/2005 - "Any protective effect of cesarean section on sexual function was limited to the early postnatal period (0-3 months), primarily to dyspareunia-related symptoms. "
11/01/1999 - "Such dyspareunia developed in women having a first (42%) or second (47%) infant, delivering vaginally (42%) or by cesarean section (29%), and lactating (41%) or not lactating (22%). "